Effect Of Galantamine On Attention In Patients With Alzheimer?s Disease Measured By Attention Questionnaire Scale (AQS) And Correlation Between The Improvement And Caregiver?s Burden Reduction | 12497
Journal of Alzheimers Disease & Parkinsonism
Like us on:
Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Attention deficits are frequently already present in the early stages of Alzheimer?s disease (AD) when testing of memory
functions shows little or no deficits. These AD patients in early stages are often described by caregivers as being unable to
concentrate and being easily distractible. Previous clinical studies suggest that the attention impairments may be early feature of
AD, responsible for part of troubles with activities of daily living and increasing caregiver?s burden.
Therefore, the efficacy of an Alzheimer?s drug for attention impairment has been focused on. According to initial studies
of galantamine?s mode of action, it is considered that galantamine might improve attention in patient with AD with its positive
allosteric modulation on cholinergic nicotinic receptors. This study was conducted to demonstrate that the effects of galantamine
on attention have influence on caregiver?s burden.
We evaluated patient?s attention and caregiver?s burden using the Attention Questionnaire Scale (AQS) and Burden Interview
(BI) respectively at baseline and after galantamine administration for 16 weeks.
After administering galantamine to 1,393 enrolled patients for 16 weeks, AQS score increased from 14.85?5.66 at baseline to
16.03?5.81 at final evaluation (p<0.0001), and BI score decreased from 36.63?17.62 at baseline to 35.13?17.10 at final evaluation
The increase in AQS score had a statistically significant correlation with the decrease in BI score (R=-0.34066, p<0.0001),
suggesting that attention improvements influence caregiver?s burden reduction.
In conclusion, treatment with galantamine for 16 weeks in patients with AD produced improvement in their attention with
AQS score increase, suggesting reduction in caregiver?s burden.
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals